Semaglutide, a glucagon-like peptide-1 receptor agonist, inhibits oral squamous cell carcinoma growth through P38 MAPK signaling pathway

被引:0
|
作者
Wang, Can [1 ,2 ]
Wu, Zhengzheng [1 ,2 ]
Zhou, Jiaying [1 ,2 ]
Cheng, Bin [1 ,2 ]
Huang, Yulei [1 ,2 ]
机构
[1] Sun Yat sen Univ, Hosp Stomatol, Guanghua Sch Stomatol, Guangzhou 510055, Peoples R China
[2] Guangdong Prov Key Lab Stomatol, Guangzhou 510080, Peoples R China
关键词
GLP-1R; Semaglutide; OSCC; P38 MAPK signaling pathway; CANCER-CELLS; ACTIVATION; APOPTOSIS; PROLIFERATION; EXENDIN-4;
D O I
10.1007/s00432-025-06154-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
AimsResearches have shown that diabetes mellitus (DM) can promote the risk and progression of oral squamous cell carcinoma (OSCC). Semaglutide, a glucagon-like peptide-1 receptor agonist, is currently employed to treat type 2 diabetes mellitus (T2DM) and obesity. This study intends to explore the potential effects and mechanism of Semaglutide on OSCC.MethodsThe expression of GLP-1R in OSCC cells and tissues was evaluated by qRT-PCR, western blot and immunohistochemistry assays. Cell proliferation, invasion, migration and apoptosis abilities were determined by relevant experiments. Western blot was employed to verify the expression of relevant proteins and examine the effect of Semaglutide on the MAPK signaling pathway. The xenograft transplantation model of OSCC was established to examine the anti-cancer effects of Semaglutide in vivo and immunohistochemistry assays were performed on tumor tissues.ResultsGLP-1R expression was elevated in OSCC cells and tissues as compared with that in normal. Semaglutide effectively inhibited the proliferation, migration and invasion of OSCC cells while concurrently promoting apoptosis. Moreover, Semaglutide specifically activated the P38 MAPK signaling pathway without significant influence on ERK1/2 or SAPK/JNK, and its pro-apoptotic effects in OSCC cells was related to P38 pathway activation. Animal experiments verified the inhibitory effect of Semaglutide on OSCC tumors in mice.ConclusionsSemaglutide exerts inhibitory actions on OSCC and may induce apoptosis in OSCC cells via the P38 MAPK signaling pathway. This study has significant implications for the treatment of patients with diabetes who are also afflicted by OSCC.
引用
收藏
页数:15
相关论文
共 50 条
  • [21] Practical applications of therapy with a glucagon-like peptide-1 receptor agonist
    Shomali, Mansur E.
    JOURNAL OF FAMILY PRACTICE, 2009, 58 (09): : S35 - S43
  • [22] Glucagon-Like Peptide-1 Receptor Agonist Treatment in Liver Cirrhosis
    Hanng, Cheng
    Danpanichkul, Pojsakorn
    Muthiah, Mark
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2024, 22 (04)
  • [23] Glucagon-Like Peptide-1 Receptor Agonist Treatment for Pediatric Obesity
    Kelly, Aaron S.
    ADVANCED THERAPIES IN PEDIATRIC ENDOCRINOLOGY AND DIABETOLOGY, 2016, 30 : 23 - 28
  • [24] Occupational allergy to glucagon-like peptide-1 receptor agonist precurser
    Johnsen, C. R.
    Rudkjoebing, L. A.
    Bartko, E.
    ALLERGY, 2023, 78
  • [25] A Review on Semaglutide: An Oral Glucagon-Like Peptide 1 Receptor Agonist in Management of Type 2 Diabetes Mellitus
    Sanjay Kalra
    Rakesh Sahay
    Diabetes Therapy, 2020, 11 : 1965 - 1982
  • [26] A Review on Semaglutide: An Oral Glucagon-Like Peptide 1 Receptor Agonist in Management of Type 2 Diabetes Mellitus
    Kalra, Sanjay
    Sahay, Rakesh
    DIABETES THERAPY, 2020, 11 (09) : 1965 - 1982
  • [27] Metformin Inhibits Proliferation and Promotes Apoptosis of Oral Squamous Cell Carcinoma Cells Through P38MAPK Signaling Pathway
    Cheng, Jie
    Yuan, Jun
    Zhou, Ran
    Zhang, Dong
    PANMINERVA MEDICA, 2020,
  • [28] Enhancing Glucagon-Like Peptide-1 Receptor Signaling in Neurodegenerative Disorders
    Li, Yazhou
    Holloway, Harold W.
    Tweedie, David
    Harvey, Brandon K.
    Mughal, Mohammed
    Hoffer, Barry J.
    Wang, Yun
    Mattson, Mark P.
    Greig, Nigel H.
    DIABETES, 2009, 58 : A367 - A367
  • [29] Electroacupuncture inhibited the spinal glial activation in neuropathic pain via glucagon-like peptide-1/Glucagon-like Peptide-1 Receptor signaling
    Zhong, Ke
    Long, Xiang
    Wan, Yun-Qiang
    Zhou, Yu
    NEUROLOGICAL SCIENCES AND NEUROPHYSIOLOGY, 2024, 41 (01): : 23 - 33
  • [30] Effects of gastric inhibitory polypeptide, glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists on Bone Cell Metabolism
    Hansen, Morten S. S.
    Tencerova, Michaela
    Frolich, Jacob
    Kassem, Moustapha
    Frost, Morten
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2018, 122 (01) : 25 - 37